What Is the Appropriate Clinical Target Volume for Esophageal Squamous Cell Carcinoma? Debate and Consensus Based on Pathological and Clinical Outcomes

Overview

Journal J Cancer

Specialty Oncology

Date 2016 Jan 29

PMID 26819644

Citations 5

Authors

Dali Han

Yinping Yuan

Xuqing Song

Yonghua Yu

Jinming Yu

Affiliations

Soon will be listed here.

Abstract

Accurate delineation of clinical target volume (CTV) is critical in the effective management of squamous cell carcinoma (SCC) of esophagus using radiation therapy. Accurate delineation may improve the probability of local control and reduce the risk of complications. However, there are no consistent standards on the proper size of the margins added to the gross tumor volume (GTV). Different institutions and radiation oncologists have discordant opinions. In this paper, we review pathological and clinical outcomes to determine the most appropriate CTV for squamous cell carcinomas (SCC) of esophagus. The CTV for esophageal carcinoma should ensure that all subclinical lesions are encompassed regardless of the physical distance. The most precise method for delineating a reasonable CTV is to combine advanced imaging techniques, such as PET/CT and EUS, which allows the detection and prediction of subclinical lesions based on tumor characteristics such as the pathological type, differentiation, T disease, length and lymph node status.

Citing Articles

Geometric and dosimetric evaluation of deep learning based auto-segmentation for clinical target volume on breast cancer.

Zhong Y, Guo Y, Fang Y, Wu Z, Wang J, Hu W J Appl Clin Med Phys. 2023; 24(7):e13951.

PMID: 36920901 PMC: 10338811. DOI: 10.1002/acm2.13951.

Assessing failure patterns of radical intent radiation strategies in patients with locally advanced carcinoma of the esophagus.

Mishra S, Ahmad F, Singh S, Singh R, Das K, Kumar S Cancer Rep (Hoboken). 2020; 4(3):e1332.

PMID: 33369258 PMC: 8222558. DOI: 10.1002/cnr2.1332.

Cardiotoxicity of radiation therapy in esophageal cancer.

Vosmik M, Hodek M, Buka D, Sykorova P, Grepl J, Paluska P Rep Pract Oncol Radiother. 2020; 25(3):318-322.

PMID: 32194352 PMC: 7078499. DOI: 10.1016/j.rpor.2020.02.005.

Subclinical Lesions of the Primary Clinical Target Volume Margin in Esophageal Squamous Cell Carcinoma and Association With FDG PET/CT.

Han D, Yuan Y, Chai J, Zhang G, Wang L, Ren A Front Oncol. 2019; 9:336.

PMID: 31114759 PMC: 6503095. DOI: 10.3389/fonc.2019.00336.

Expression of and long-chain non-coding RNAs in esophageal squamous cell carcinoma tissues is predictive of patient prognosis.

Kang K, Huang Y, Li H, Guo S Arch Med Sci. 2018; 14(4):752-759.

PMID: 30002691 PMC: 6040126. DOI: 10.5114/aoms.2018.73713.

References

von Rahden B, Stein H, Feith M, Becker K, Siewert J . Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2005; 23(4):874-9. DOI: 10.1200/JCO.2005.12.151. View

Tsutsui S, Kuwano H, Watanabe M, Kitamura M, Sugimachi K . Resection margin for squamous cell carcinoma of the esophagus. Ann Surg. 1995; 222(2):193-202. PMC: 1234778. DOI: 10.1097/00000658-199508000-00012. View

Nishimaki T, Suzuki T, Tanaka Y, Aizawa K, Hatakeyama K, Muto T . Intramural metastases from thoracic esophageal cancer: local indicators of advanced disease. World J Surg. 1996; 20(1):32-7. DOI: 10.1007/s002689900006. View

Nishimaki T, Suzuki T, Kanda T, Obinata I, Komukai S, Hatakeyama K . Extended radical esophagectomy for superficially invasive carcinoma of the esophagus. Surgery. 1999; 125(2):142-7. View

Tanaka A, Matsumura E, Yosikawa H, Uchida T, Machidera N, Kubo R . An evaluation of neural invasion in esophageal cancer. Surg Today. 1998; 28(9):873-8. DOI: 10.1007/s005950050245. View

Kuwano H, Ohno S, Matsuda H, Mori M, Sugimachi K . Serial histologic evaluation of multiple primary squamous cell carcinomas of the esophagus. Cancer. 1988; 61(8):1635-8. DOI: 10.1002/1097-0142(19880415)61:8<1635::aid-cncr2820610822>3.0.co;2-u. View

Nakamura T, Hatooka S, Kodaira T, Tachibana H, Tomita N, Nakahara R . Determination of the irradiation field for clinical T1-T3N0M0 thoracic/abdominal esophageal cancer based on the postoperative pathological results. Jpn J Clin Oncol. 2008; 39(2):86-91. DOI: 10.1093/jjco/hyn131. View

Chen J, Xie J, Ling Y, Li P, Yan S, Xi S . The prognostic effect of perineural invasion in esophageal squamous cell carcinoma. BMC Cancer. 2014; 14:313. PMC: 4016635. DOI: 10.1186/1471-2407-14-313. View

Takubo K, Sasajima K, Yamashita K, Tanaka Y, Fujita K . Prognostic significance of intramural metastasis in patients with esophageal carcinoma. Cancer. 1990; 65(8):1816-9. DOI: 10.1002/1097-0142(19900415)65:8<1816::aid-cncr2820650825>3.0.co;2-l. View

10.

Button M, Morgan C, Croydon E, Roberts S, Crosby T . Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008; 73(3):818-23. DOI: 10.1016/j.ijrobp.2008.04.062. View

11.

Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert H . Incidence and prognostic significance of vascular and neural invasion in squamous cell carcinomas of the esophagus. Int J Cancer. 1995; 61(3):333-6. DOI: 10.1002/ijc.2910610310. View

12.

Cooper J, Guo M, Herskovic A, Macdonald J, Martenson Jr J, Al-Sarraf M . Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281(17):1623-7. DOI: 10.1001/jama.281.17.1623. View

13.

Koenig A, Prenzel K, Bogoevski D, Yekebas E, Bubenheim M, Faithova L . Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol. 2008; 16(2):454-62. DOI: 10.1245/s10434-008-0169-7. View

14.

Hosch S, Stoecklein N, Pichlmeier U, Rehders A, Scheunemann P, Niendorf A . Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol. 2001; 19(7):1970-5. DOI: 10.1200/JCO.2001.19.7.1970. View

15.

Gao X, Qiao X, Wu F, Cao L, Meng X, Dong Z . Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys. 2007; 67(2):389-96. DOI: 10.1016/j.ijrobp.2006.09.015. View

16.

Minsky B . Primary combined-modality therapy for esophageal cancer. Oncology (Williston Park). 2006; 20(5):497-505. View

17.

Kuwano H, Masuda N, Kato H, Sugimachi K . The subepithelial extension of esophageal carcinoma for determining the resection margin during esophagectomy: a serial histopathologic investigation. Surgery. 2002; 131(1 Suppl):S14-21. DOI: 10.1067/msy.2002.119289. View

18.

Natsugoe S, Matsumoto M, Okumura H, Nakashima S, Higashi H, Uenosono Y . Initial metastatic, including micrometastatic, sites of lymph nodes in esophageal squamous cell carcinoma. J Surg Oncol. 2004; 89(1):6-11. DOI: 10.1002/jso.20172. View

19.

Jiang L, Zhao X, Meng X, Yu J . Involved field irradiation for the treatment of esophageal cancer: is it better than elective nodal irradiation?. Cancer Lett. 2014; 357(1):69-74. DOI: 10.1016/j.canlet.2014.11.045. View

20.

Morita M, Araki K, Saeki H, Sakaguchi Y, Baba H, Sugimachi K . Risk factors for multicentric occurrence of carcinoma in the upper aerodigestive tract-analysis with a serial histologic evaluation of the whole resected-esophagus including carcinoma. J Surg Oncol. 2003; 83(4):216-21. DOI: 10.1002/jso.10276. View